Recommended Topic Related To:

Pavulon

"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...

Pavulon

PAVULON®
(pancuronium bromide) Injection

NOT FOR USE IN NEONATES
CONTAINS BENZYL ALCOHOL

THIS DRUG SHOULD BE ADMINISTERED BY ADEQUATELY TRAINED INDIVIDUALS FAMILIAR WITH ITS ACTIONS, CHARACTERISTICS, AND HAZARDS.

DRUG DESCRIPTION

PAVULON® (pancuronium bromide) injection is a nondepolarizing neuromuscular blocking agent chemically designated as the aminosteroid 2 ß, 16 ß - dipiperidino-5α-androstane3α, 17-β diol diacetate dimethobromide.

The structural formula is:

PAVULON®
(pancuronium bromide) Structural Formula Illustration

PAVULON® (pancuronium bromide injection) is supplied as a sterile, isotonic, nonpyrogenic solution for injection. Each mL contains 1 mg or 2 mg pancuronium bromide, 2 mg sodium acetate and 1% benzyl alcohol as preservative. The solution is adjusted to isotonicity with sodium chloride and to a pH of 4 with acetic acid and/or sodium hydroxide; water is used as the solvent.

Last reviewed on RxList: 1/11/2011
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


NIH talks about Ebola on WebMD